Today Digest - 2026-10-23

Daily overview

Today’s selection is united by an applied, decision-oriented orientation, in which established quantitative frameworks are used to inform screening and prevention choices across cancer control, infectious disease and cardiovascular care. The methods are largely conventional: a retrospective comparison of risk-assessment strategies using sensitivity, specificity, likelihood ratios and paired tests, together with two economic evaluations built on a static decision tree and a cohort Markov model. Common directions include contextualising model performance beyond the populations in which tools were originally developed, stratifying outcomes by subgroup risk, and using national data to parameterise policy scenarios in lower-resource settings. Cross-disciplinary development is visible in the pairing of clinical risk prediction with health economic reasoning, including price thresholds, budget impact and comparisons of universal versus risk-targeted strategies. A recurring limitation in this set is that uncertainty handling is sparsely described, which makes calibration and decision-making under uncertainty salient areas for scrutiny. Only one paper matched a provisional seed trend tag, so this set offers little evidence on emerging topics; the trend snapshot, which compares a 30-day recent window of 7262 corpus records with a 180-day baseline, is best treated as context rather than confirmation. For the research profile, today’s set mainly reinforces core interests in health economics, screening optimisation and policy evaluation, and highlights opportunities for more rigorous uncertainty quantification.

AI-generated synthesis (Claude via claude-code-action, model sonnet) of today’s selected papers and the current trend snapshot; it interprets verified metadata and does not summarize papers individually.

Recommendations

Coverage note: 3 papers met the eligibility and verification rules today (maximum 10). The list is not padded with stale or weakly related papers.

1. Beyond Screening Populations: Context-Dependent Performance of Lung Cancer Risk Assessment Strategies in a Diagnostically Enriched Cohort.

Abstract (original abstract, verbatim from Europe PMC)

Background/Objectives: Lung cancer screening with low-dose computed tomography has been shown to reduce disease-specific mortality, but optimal strategies for identifying high-risk individuals remain debated. This retrospective, single-center cohort study examined the context-dependent behavior of two individualized lung cancer risk prediction models, PLCOm2012 and the Bach model, and National Comprehensive Cancer Network (NCCN) screening criteria when retrospectively applied to hospitalized patients undergoing diagnostic evaluation. The study was not designed as an external validation of these approaches for their intended screening purpose, but rather to assess their ability to discriminate between patients with and without prevalent lung cancer in a diagnostically enriched clinical population. Methods: Among 254 patients in the overall cohort, 86 had histopathologically confirmed primary lung cancer. For the primary head-to-head comparison, a common analytic cohort of 133 current or former smokers for whom all three approaches could be evaluated was used; 56 of these patients had lung cancer. Results: PLCOm2012 demonstrated high sensitivity (87.5%) but low specificity (15.6%), whereas the Bach model, at the cohort-derived exploratory threshold of ≥0.49%, showed lower sensitivity (42.9%) and higher specificity (57.1%). NCCN criteria yielded the highest sensitivity (96.4%) but very low specificity (3.9%). Likelihood ratios were close to unity for all three approaches, indicating limited discrimination in this diagnostically enriched population. Paired analyses demonstrated significant differences in sensitivity and specificity between several of the threshold-based approaches, whereas continuous discrimination did not differ significantly between PLCOm2012 and the Bach model; overall discrimination remained limited in this diagnostically enriched cohort. Conclusions: These findings highlight the context-dependent performance of screening-oriented risk assessment tools and indicate that results derived from asymptomatic screening populations should not be directly extrapolated to hospitalized patients undergoing diagnostic evaluation.

Author keywords: Bach; PLCOm2012; lung cancer; risk prediction; screening eligibility

MeSH terms: No MeSH terms in verified sources

AI-assigned topic tags (AI-generated classification, not author keywords): Cancer screening optimization

Matched emerging trend tags: Cancer screening optimization (trend score 0.31)

Score breakdown (weighted sum computed in Python; scoring version scoring-d37b266615)

Methodological assessment (AI interpretation, preliminary — abstract only): Incremental application. Retrospective single-centre comparison of PLCOm2012, the Bach model and NCCN criteria (n=133 common cohort) using sensitivity, specificity, likelihood ratios and paired tests. Not an external validation as stated by the authors.

Why it is recommended for you (AI interpretation): Cautionary evidence on transporting screening eligibility risk models outside screening populations.

Evidence and confidence limitations: Exploratory threshold derived in the evaluation cohort Hospitalized, diagnostically enriched cohort; not a screening population Small single-centre retrospective sample

2. Optimizing pneumococcal prevention in South African older adults: Cost-effectiveness of PCV20 versus PPSV23 in the context of HIV-associated risk.

Abstract (original abstract, verbatim from PubMed)

Pneumococcal disease remains a major cause of morbidity and mortality among older adults in South Africa, particularly among people living with HIV. Evidence on the cost-effectiveness of Prevnar 20 (PCV20) vs. Pneumovax 23 (PPSV23) vaccine in this setting remains limited. This study was conducted to evaluate the cost-effectiveness of PCV20 compared with PPSV23 vaccine among adults aged ≥65y in South Africa, and to assess the impact of HIV stratification on economic outcomes. A static decision-tree model was developed from the South African public healthcare payer perspective. The analysis incorporated invasive pneumococcal disease, pneumococcal community-acquired pneumonia, quality-adjusted life-years, maximum acceptable price, and 5y budget impact. HIV-stratified incidence and CD4-adjusted vaccine effectiveness were included. In the general population, PCV20 provided greater health benefits than PPSV23 but was not cost-effective at the current base-case price (USD 20.00/dose), with an ICER of USD 17,323/QALY. Price was the main driver of cost-effectiveness. In contrast, targeted vaccination of older adults living with HIV was economically favorable, with an ICER of USD 2,104/QALY under national incidence assumptions, and even stronger results in high-burden settings. The cost-effectiveness of PCV20 in South Africa is contingent upon the price of vaccine and risk-based targeting. Vaccinating all older adults universally may not be cost-effective at current prices, suggesting that targeted vaccination of older adults with HIV represents a more efficient strategy.

Author keywords: HIV stratification; PCV20; PPSV23; South Africa; cost-effectiveness analysis

MeSH terms: Humans; South Africa; Cost-Benefit Analysis; Pneumococcal Vaccines; Aged; Cost-Effectiveness Analysis; HIV Infections; Female; Pneumococcal Infections; Male; Aged, 80 and over; Community-Acquired Pneumonia; Incidence; Quality-Adjusted Life Years

AI-assigned topic tags (AI-generated classification, not author keywords): No tags assigned

Matched emerging trend tags: No matched trend tags

Score breakdown (weighted sum computed in Python; scoring version scoring-d37b266615)

Methodological assessment (AI interpretation, preliminary — abstract only): Existing method applied to a new problem. Static decision-tree with HIV-stratified incidence, CD4-adjusted effectiveness, maximum acceptable price and 5-year budget impact. Uncertainty handling not described.

Why it is recommended for you (AI interpretation): Relevant illustration of risk-targeted versus universal vaccination economics in a high-HIV-burden setting.

Evidence and confidence limitations: Static model; no transmission dynamics insufficient methods information in abstract

3. Cost-utility of expanded hypertension screening and treatment among adults covered by Peru’s Seguro Integral de Salud: a Markov model using national data.

Abstract (original abstract, verbatim from PubMed)

BACKGROUND: We assessed the cost-utility of expanding hypertension screening, diagnosis, and treatment among adults covered by Peru’s Seguro Integral de Salud (SIS). RESEARCH DESIGN AND METHODS: Analyses assembled in May 2026 used a 10-year cohort Markov model parameterized with the 2024 Peruvian Demographic and Family Health Survey (ENDES), SIS administrative data for 2022-2024, and published parameters. Universal and risk-targeted scenarios were compared with population-specific usual care, using S/ 25,007 per quality-adjusted life-year (QALY). RESULTS: The baseline sample included 6,098 adults aged 40-74 years; hypertension prevalence was 28.9%. Universal 80-80-80 expansion averted 60.7 cardiovascular events and 6.1 cardiovascular deaths and gained 51.3 QALYs per 100,000 eligible adults. Incremental cost was S/ 7,784,979, with an incremental cost-effectiveness ratio (ICER) of S/ 151,686/QALY. The scenario targeting 10-year cardiovascular risk ≥10% had an ICER of S/ 60,171/QALY in its eligible subgroup. CONCLUSIONS: All scenarios exceeded the threshold. Lower targeted-scenario ICERs concern different eligible populations. Estimates depend on modeled effects, the 10-year horizon, and exclusion of event-related savings.

Author keywords: Cost-utility analysis; Peru; economic models; hypertension; quality-adjusted life years; screening

MeSH terms: No MeSH terms in verified sources

AI-assigned topic tags (AI-generated classification, not author keywords): No tags assigned

Matched emerging trend tags: No matched trend tags

Score breakdown (weighted sum computed in Python; scoring version scoring-d37b266615)

Methodological assessment (AI interpretation, preliminary — abstract only): Incremental application. Cohort Markov model with national survey inputs; universal and risk-targeted scenarios. Uncertainty methods are not described in the abstract.

Why it is recommended for you (AI interpretation): Background for evaluating universal versus risk-targeted screening and treatment in a middle-income setting.

Evidence and confidence limitations: Not a profile disease area insufficient methods information in abstract

Methodology and coverage

Publication horizon: 30 days before 2026-10-23; retrieval overlap 7 days; trend windows 30/180 days.

Providers: crossref: ok; europe_pmc: ok; medrxiv: ok; openalex: ok; pubmed: ok.

Versions: pipeline 0.1.0, scoring scoring-d37b266615, rubric rubric-83f3f3d704, prompts 1.0, trend snapshot trend-v1-db2b77f24b, configuration 14df7e0889.

Source metadata (titles, authors, dates, identifiers, abstracts, keywords, MeSH) comes verbatim from the named providers. Assessments, tags and the overview marked as AI interpretation are generated by Claude from that metadata and may be wrong; novelty judgements are preliminary when based on abstracts only.